Leerink Partnrs Issues Positive Outlook for LRMR Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Research analysts at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a research report issued to clients and investors on Wednesday, April 30th. Leerink Partnrs analyst J. Park now forecasts that the company will post earnings of ($0.52) per share for the quarter, up from their prior estimate of ($0.61). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Leerink Partnrs also issued estimates for Larimar Therapeutics’ Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.70) EPS, FY2025 earnings at ($2.28) EPS, FY2026 earnings at ($2.61) EPS, FY2027 earnings at ($2.34) EPS and FY2028 earnings at ($1.26) EPS.

Several other analysts also recently issued reports on LRMR. Citigroup restated a “buy” rating on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Truist Financial began coverage on shares of Larimar Therapeutics in a research note on Wednesday, January 29th. They issued a “buy” rating and a $18.00 price target on the stock. Guggenheim reissued a “buy” rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Robert W. Baird lowered their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, March 25th. Finally, HC Wainwright lifted their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, March 25th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $19.63.

Larimar Therapeutics Stock Down 9.4 %

Larimar Therapeutics stock opened at $2.69 on Monday. The company’s 50-day moving average price is $2.36 and its two-hundred day moving average price is $4.17. The stock has a market cap of $172.24 million, a P/E ratio of -2.34 and a beta of 0.93. Larimar Therapeutics has a twelve month low of $1.61 and a twelve month high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Institutional Trading of Larimar Therapeutics

Several large investors have recently made changes to their positions in LRMR. SG Americas Securities LLC boosted its holdings in shares of Larimar Therapeutics by 35.1% in the 4th quarter. SG Americas Securities LLC now owns 19,391 shares of the company’s stock valued at $75,000 after purchasing an additional 5,042 shares in the last quarter. Barclays PLC lifted its position in shares of Larimar Therapeutics by 321.2% during the 3rd quarter. Barclays PLC now owns 60,032 shares of the company’s stock worth $393,000 after buying an additional 45,781 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Larimar Therapeutics by 18.7% in the third quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company’s stock valued at $143,000 after buying an additional 3,425 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in Larimar Therapeutics by 23.5% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock valued at $8,127,000 after acquiring an additional 399,123 shares during the last quarter. Finally, Blue Owl Capital Holdings LP raised its stake in Larimar Therapeutics by 11.7% during the fourth quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company’s stock worth $18,007,000 after acquiring an additional 486,211 shares in the last quarter. Institutional investors and hedge funds own 91.92% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.